×

Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that 2 oral presentations and 6 posters highlighting its development programs for lysosomal storage diseases will be included at the 11th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 9-13, 2015 in Orlando, FL.

Oral Platform Presentations:

Fabry Disease:

  • Long-Term Efficacy and Safety of Migalastat Compared to Enzyme Replacement Therapy in Fabry Disease: Phase 3 Study Results – Derralynn Hughes, DPhil, University College London (Thursday, February 12 at 9:45 a.m. ET)

Pompe Disease:

  • Novel Recombinant Human Acid Alpha-Glucosidase with Optimal Glycosylation is Significantly Better than Standard of Care Enzyme Replacement for Glycogen Clearance in Skeletal Muscles of Gaa Knock-out Mice. – Russell Gotschall, Amicus Therapeutics, Inc. (Tuesday, February 10 at 4:15 p.m. ET)

Posters: Tuesday, February 10 - Thursday, February 12, 4:30-6:30 p.m. ET

Fabry Disease:

  • Long-Term Efficacy and Safety of Migalastat Compared to Enzyme Replacement Therapy in Fabry Disease: Phase 3 Study Results – Derralynn Hughes, DPhil, University College London (Poster #115)
  • Migalastat Reduces Left Ventricular Mass Index in Fabry Patients Naïve to ERT and Previously Treated with ERT – Daniel Bichet, M.D., M.Sc., University of Montreal (Poster #LB-2 – Late Breaker)
  • Improvement in Gastrointestinal Symptoms Observed in the Phase 3 FACETS Study of Migalastat in Fabry Patients – Raphael Schiffmann, M.D., M.H.Sc., Baylor University (Poster #230)
  • Accurate Quantitation of Plasma Globotriaosylsphingosine (lyso-Gb3) in Normal Individuals and Fabry Patients by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) – Rick Hamler, Amicus Therapeutics, Inc. (Poster #100)

Pompe Disease:

  • Novel Recombinant Human Acid Alpha-Glucosidase with Optimal Glycosylation is Significantly Better than Standard of Care Enzyme Replacement for Glycogen Clearance in Skeletal Muscles of Gaa Knock-out Mice. – Russell Gotschall, Amicus Therapeutics, Inc. (Poster #94)
  • Histological Examination of the Effect of a Highly Phosphorylated Proprietary Recombinant Human Acid Alpha-Glucosidase on Glycogen Reduction in Disease-Relevant Muscles of Pompe Mice – Yi Lun, Amicus Therapeutics, Inc. (Poster #162)

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

FOLD–G

CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Director, Investor Relations spellegrino@amicusrx.com (609) 662-5044 Media: Pure Communications Dan Budwick dan@purecommunicationsinc.com (973) 271-6085

Source:Amicus Therapeutics, Inc.